Kamada (NASDAQ:KMDA) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

KMDA has been the topic of a number of other research reports. TheStreet raised shares of Kamada from a “c” rating to a “b” rating in a research note on Friday, February 9th. Zacks Investment Research raised shares of Kamada from a “sell” rating to a “hold” rating in a research note on Friday, February 9th. HC Wainwright reissued a “buy” rating on shares of Kamada in a research note on Thursday, February 8th. Finally, Chardan Capital started coverage on shares of Kamada in a research note on Friday, February 2nd. They issued a “buy” rating and a $7.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $7.00.

How to Become a New Pot Stock Millionaire

Shares of Kamada (NASDAQ KMDA) opened at $5.15 on Tuesday. The firm has a market cap of $209.37, a PE ratio of 30.30 and a beta of 1.12. Kamada has a 52 week low of $3.75 and a 52 week high of $8.61. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.30 and a quick ratio of 2.58.

Kamada (NASDAQ:KMDA) last posted its earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.10. The business had revenue of $35.71 million for the quarter, compared to analysts’ expectations of $32.90 million. Kamada had a net margin of 6.71% and a return on equity of 9.06%. equities analysts expect that Kamada will post 0.21 EPS for the current year.

A number of institutional investors have recently modified their holdings of KMDA. Vanguard Group Inc. grew its stake in Kamada by 6.5% during the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after buying an additional 28,382 shares during the last quarter. Worth Venture Partners LLC bought a new stake in Kamada during the third quarter worth about $246,000. Analyst IMS Investment Management Services Ltd. grew its stake in Kamada by 125.5% during the third quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after buying an additional 50,000 shares during the last quarter. Jane Street Group LLC bought a new stake in Kamada during the third quarter worth about $112,000. Finally, ARK Investment Management LLC bought a new stake in Kamada during the fourth quarter worth about $251,000. 9.14% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2018/03/14/valuengine-downgrades-kamada-kmda-to-sell.html.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.